Cargando…

Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer

SIMPLE SUMMARY: Recent studies re-classified the c.5339T->C; p.Leu1780Pro (L1780P) BRCA1 missense mutation as “likely pathogenic” in ACMG classification, which shows a high prevalence in the Korean population. This study aims to reveal the molecular mechanisms and therapeutic relevance of BRCA1 L...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jeong Dong, Ryu, Won-Ji, Han, Hyun Ju, Kim, Tae Yeong, Kim, Min Hwan, Sohn, Joohyuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139203/ https://www.ncbi.nlm.nih.gov/pubmed/35626017 http://dx.doi.org/10.3390/cancers14102405

Ejemplares similares

Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant
por: Park, Hyung Seok, et al.
Publicado: (2020)

Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models
por: Park, Hyung Seok, et al.
Publicado: (2019)

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
por: Sohn, Joohyuk, et al.
Publicado: (2014)

Peer review of the pesticide risk assessment of the active substance Beauveria bassiana strain PPRI 5339
por: Arena, Maria, et al.
Publicado: (2018)

Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia
por: Mahfoudh, Wijden, et al.
Publicado: (2019)

Functional and Structural Analysis of C-Terminal BRCA1 Missense Variants
por: Quiles, Francisco, et al.
Publicado: (2013)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

Understanding and predicting the functional consequences of missense mutations in BRCA1 and BRCA2
por: Aljarf, Raghad, et al.
Publicado: (2022)

BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012)

Development of functional assays for BRCA1 missense mutations
por: Sturdy, A, et al.
Publicado: (2008)

BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer
por: Francies, F. Z., et al.
Publicado: (2015)

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
por: Pogoda, Katarzyna, et al.
Publicado: (2020)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
por: Glodzik, Dominik, et al.
Publicado: (2020)

Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML
por: Hart, Steven N., et al.
Publicado: (2020)

Multifactorial Likelihood Assessment of BRCA1 and BRCA2 Missense Variants Confirms That BRCA1:c.122A>G(p.His41Arg) Is a Pathogenic Mutation
por: Whiley, Phillip J., et al.
Publicado: (2014)

Systematic misclassification of missense variants in BRCA1 and BRCA2 “coldspots”
por: Dines, Jennifer N., et al.
Publicado: (2020)

Comprehensive clinical characterization of patients with BRCA1: c.5017_5019del germline variant
por: Bang, Yoon Ju, et al.
Publicado: (2022)

Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
por: Ryu, Won-Ji, et al.
Publicado: (2021)

Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer
por: MAKSIMENKO, JELENA, et al.
Publicado: (2014)

Gene-specific machine learning for pathogenicity prediction of rare BRCA1 and BRCA2 missense variants
por: Kang, Moonjong, et al.
Publicado: (2023)

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
por: Bouwman, Peter, et al.
Publicado: (2010)

Hereditary protein C deficiency with recurrent thrombosis: identification of a missense mutation (C6218T).
por: Song, K. S., et al.
Publicado: (1998)

Erratum: Bilateral Triple Negative Invasive Ductal Breast Carcinoma in a BRCA1 Mutation Carrier with Discrepant Pathologic Response to Neoadjuvant Chemotherapy
por: Shin, Gi Won, et al.
Publicado: (2020)

Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer
por: Ferreira, Elisa Napolitano, et al.
Publicado: (2019)

Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient
por: Zheng, Yuanting, et al.
Publicado: (2021)

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
por: Young, SR, et al.
Publicado: (2009)

Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia
por: PALOMBA, GRAZIA, et al.
Publicado: (2014)

Triple-negative Breast Cancer Arising in a Fibroadenoma in BRCA 1 Mutated Patient
por: Brunetti, Nicole, et al.
Publicado: (2022)

A Novel HNPP Phenotype in Charcot-Marie-Tooth Type 2E With c.1319C>T Missense Mutation in the NEFL Gene
por: Choi, Ko-Eun, et al.
Publicado: (2022)

Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer
por: Luo, Yanli, et al.
Publicado: (2018)

Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

A missense mutation in the BRCA2 gene in three siblings with ovarian cancer.
por: Roth, S., et al.
Publicado: (1998)

Gene Regulatory Network Analysis for Triple-Negative Breast Neoplasms by Using Gene Expression Data
por: Jung, Hee Chan, et al.
Publicado: (2017)

The role of BRCA status on prognosis in patients with triple-negative breast cancer
por: Xie, Yuxin, et al.
Publicado: (2017)

Mutation Analysis of BRCA1, BRCA2, PALB2 and BRD7 in a Hospital-Based Series of German Patients with Triple-Negative Breast Cancer
por: Pern, Franziska, et al.
Publicado: (2012)

Prevalence of BRCA1 and BRCA2 mutations in Japanese patients with triple-negative breast cancer: A single institute retrospective study
por: Fujisawa, Fumie, et al.
Publicado: (2021)

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
por: Lips, E H, et al.
Publicado: (2013)

Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer
por: Ye, Fugui, et al.
Publicado: (2021)

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
por: Kalra, Maitri, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l9bes977ti50dt92mu5bsl8dk8